Basilea Pharmaceutica AG

SWF:BSLN ISIN:CH0011432447

May 26, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

Basilea Pharmaceutica AG Company Summary

Basilea Pharmaceutica AG (SWF:BSLN) is a Switzerland-based research and development biopharmaceutical Company. The Company focuses its activities on the areas of antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. The Company's late-stage product portfolio comprises novel treatments for resistant bacterial infections, systemic fungal infections, and severe skin diseases. The Company's portfolio includes two commercialized drugs, alitretinoin and ceftobiprole, one investigational drug, isavuconazole, in phase III, as well as substantial early-state programs.

COMPANY DATA

	Principal Sector	Ag Biotechnology

	Principal Industry	Healthcare

	Homepage	www.basilea.com

Key Developments: Basilea Pharmaceutica AG

	Asian Markets Overview of February 25 FEB 25, 2010 13:30 - Article Views: 3,957 Asian markets mostly dropped on Wednesday. Resources shares across the region were hit by falling metals prices. Japan's Nikkei 225 fell 1.5 per cent, South Korea's Kospi shed 1.0 per cent and Hong Kong's Hang Seng Index lost 0.8 per cent. The markets also weighed down by U.S. consumer confidence and German business sentiment. But China's Shanghai Composite rebounded 1.3 per cent as monetary tightening worries eased.

	Basilea Pharmaceutica AG (VTX:BSLN) Ceftobiprole, A New Anti-mrsa Broad-spectrum Antibiotic, Receives Approval By Swissmedic NOV 13, 2008 16:17 - Article Views: 1,567 Basilea Pharmaceutica AG (VTX:BSLN) Basel, Switzerland, November 13, 2008 - Basilea Pharmaceutica Ltd. announces that ceftobiprole (Zevtera(TM)), the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Swissmedic for the treatment of complicated skin and soft tissue infections including diabetic foot infections.

	Basilea Pharmaceutica AG (SWF:BSLN) Basilea Presents Research Data At ICAAC/IDSA On Novel Antibiotic Addressing The Emerging Threat From Multi-resistant Gram-negative bacteria OCT 27, 2008 17:17 - Article Views: 1,541 Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 27, 2008 - Multi-resistant Gram-negative bacteria are causing increasing concern around the world. Basilea's novel antibiotic BAL30072 demonstrates potent in-vitro activity against some of the most difficult to treat multi-resistant Gram-negative bacteria.

	Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives Marketing Authorization In France OCT 21, 2008 16:17 - Article Views: 1,470 Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 21, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the French Health Products Safety Agency (Agence Française de Sécurité Sanitaire des Produits de Santé [AFSSAPS]).

	Basilea Pharmaceutica AG (SWF:BSLN) Basilea Announces New Data To Be Presented On Ceftobiprole And Isavuconazole At ICAAC/IDSA OCT 20, 2008 15:17 - Article Views: 1,250 Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 20, 2008 - New data on Basilea's late-stage anti-infectives ceftobiprole and isavuconazole will be presented at the upcoming joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA) in Washington DC.

	Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives Marketing Authorization In Finland OCT 15, 2008 15:17 - Article Views: 1,299 Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 15, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by Finland's National Agency for Medicines (NAM).

	Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives Marketing Authorization In Germany OCT 6, 2008 15:17 - Article Views: 663 Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 6, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the German health authority "Bundesinstitut für Arzneimittel und Medizinprodukte" (BfArM).

	Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives Marketing Authorization In Denmark SEP 22, 2008 15:17 - Article Views: 686 Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 22, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Danish Medicines Agency (DKMA).

	Basilea Pharmaceutica AG (SWF:BSLN) FDA Accepts For Review The Complete Response To Ceftobiprole NDA Approvable Letter SEP 15, 2008 15:17 - Article Views: 578 Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 15, 2008 - Basilea Pharmaceutica Ltd. announces that the Food and Drug Administration (FDA) has accepted for review the Complete Response to the ceftobiprole New Drug Application (NDA) Approvable Letter.

	Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives First National Marketing Authorization In The UK SEP 8, 2008 15:17 - Article Views: 640 Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 8, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.